Quick Facts: Decara

• Supports the maintenance of adequate vitamin D levels.
• Contributes to the absorption of dietary calcium.
• May assist in maintaining bone health in conjunction with calcium.

---

Decara is a therapeutic option used to address or prevent conditions related to insufficient levels of vitamin D in the body. Maintaining sufficient vitamin D levels is necessary for the proper absorption of calcium from the diet, which supports the maintenance of bone health. This therapeutic support is relevant for individuals identified as having a deficiency or insufficiency based on clinical assessment.

In addition to its central role in bone mineralization, adequate vitamin D status may favorably influence the maintenance of healthy immune and neuromuscular function. This medication is utilized as part of a complete management plan that may include dietary modifications and other supplements, as determined by a healthcare provider. The application of this component is focused on supporting biological functions related to vitamin D sufficiency.

Decara (Losartan Potassium) is subject to specific regulatory eligibility rules that define the population permitted to use the medicine. These rules are derived from official government labeling.

Contraindicated Populations

The use of Decara is strictly prohibited (contraindicated) in the second and third trimesters of pregnancy due to the risk of fetal injury and death. It is also contraindicated for individuals with known hypersensitivity to Losartan Potassium or any of its components, and for patients with severe hepatic impairment.

A further contraindication applies to patients with Diabetes Mellitus or Renal Impairment (GFR below 60 mL/min/1.73 m^2) who are simultaneously taking Aliskiren.

Age and Condition-Based Rules

The medicine is generally approved for adults for all labeled uses. In children, eligibility is restricted: it is approved only for the treatment of hypertension and only for those aged 6 years and older.

Use is not recommended for children under 6 years or those with a GFR below 30 mL/min/1.73 m^2. Use in patients who are volume- or salt-depleted requires correction of the condition prior to administration. The drug is not recommended for women who are breastfeeding.

Decara Interactions with other medicines and products

Official regulatory documents define the interaction profile of Decara (Losartan Potassium) across pharmacodynamic and pharmacokinetic mechanisms, establishing specific constraints for co-administration. No timing-based separation is formally required in the regulatory labeling.

Interaction Entity	Classification	Official Outcome/Restriction
Aliskiren (in specific patients)	Contraindicated Combination	Prohibited in patients with diabetes mellitus or those with renal impairment (GFR < 60 mL/min/1.73 m^2) [2.4].
Potassium-Sparing Diuretics (e.g., Amiloride, Spironolactone)	Pharmacodynamic Synergism	Increased risk of hyperkalemia (high serum potassium) [2.3].
Lithium	Reduced Clearance	Losartan reduces the clearance of Lithium, potentially leading to increased serum concentration and toxicity [2.4].
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)	Pharmacodynamic/Renal Risk	Reduces the antihypertensive effect; increases risk of renal function deterioration, especially in the elderly [2.3].
Fluconazole (CYP2C9 Inhibitor)	Pharmacokinetic Modification	Increases the exposure (AUC) of Losartan while decreasing the exposure of its active metabolite [1.5].
Rifampin (CYP Inducer)	Pharmacokinetic Modification	Reduces the exposure (AUC) of both Losartan and its active metabolite [1.5].

Interactions with Food, Alcohol, and Supplements:

Co-administration with Potassium Supplements or potassium-containing salt substitutes is associated with an increased risk of hyperkalemia [4.2]. Although Losartan can be taken with food, certain food products like grapefruit may interfere with metabolism, potentially reducing effectiveness [4.1]. Alcohol may have an additive effect in lowering blood pressure [4.1]. The risk of interaction with NSAIDs is noted as being heightened in patients with pre-existing renal impairment [2.3].

**Decara is a monoclonal antibody that targets the RANKL (Receptor Activator of Nuclear Factor kappa B Ligand) protein. It binds with high specificity to RANKL in its soluble and membrane-bound forms, thereby preventing its interaction with the RANK receptor expressed on osteoclast precursor cells.***

This antagonism blocks the downstream signaling cascade mediated by TRAF6 (Tumor necrosis factor Receptor-Associated Factor 6), which otherwise facilitates the translocation and activation of the NF- κB family of transcription factors. Consequently, Decara suppresses the cellular differentiation of osteoclast precursors and reduces the lifespan of mature osteoclasts. The resulting decrease in osteoclast function modulates bone resorption activity, shifting the overall balance of bone remodeling.

Decara (cholecalciferol, or Vitamin D3) is an oral medication used to treat or prevent Vitamin D deficiency. It is crucial to use this medication exactly as prescribed by a healthcare provider, or to follow the instructions provided on the package insert if using an over-the-counter product. Dosing schedules for Decara can vary significantly, often ranging from a daily dose to a weekly or even monthly regimen, depending on the patient's specific medical condition, age, and blood levels of Vitamin D.

Administration Guidelines

Decara is a fat-soluble vitamin and is best absorbed when taken with food or a meal that contains fat, which helps to increase its bioavailability. The correct method of administration may differ based on the dosage form:

Dosage Form	Instruction
Capsule/Softgel	Swallow the capsule whole with water. Do not crush or chew.
Wafer	The wafer must be chewed or crushed thoroughly before swallowing. Do not swallow it whole.
Liquid/Solution	Measure the dose precisely using the calibrated measuring device provided with the product, not a standard household spoon. Liquid may be dropped directly into the mouth or mixed with food or a beverage like water or juice.

Important Considerations

• Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular dosing schedule. Do not take two doses at the same time to compensate for a missed dose.
• Vitamin D Intake: Do not use additional Vitamin D supplements, including those in multivitamins, unless specifically directed by a healthcare provider, to avoid the risk of excessive intake and hypervitaminosis D.
• Storage: Store Decara at room temperature, away from heat, moisture, and direct light, and keep it out of reach of children and pets.

Research evidence / Overview of studies for Decara

Decara (Losartan Potassium) was studied for its use in research contexts involving high blood pressure and specific cardiovascular and kidney-related conditions. The body of evidence related to Decara primarily comes from Randomized Controlled Trials (RCTs), which are considered a key type of study design, along with large-scale systematic reviews and observational data.

Research examining the use in Hypertension (High Blood Pressure) involved RCTs that monitored changes in systolic and diastolic blood pressure levels. Findings from these trials describe patterns observed in the studies related to the evolution of blood pressure measurements and the maintenance of blood pressure control over the study period. Comparative evidence is lacking for certain long-term outcomes against all other antihypertensive medications.

For Cardiovascular Risk Reduction, Decara was studied for specific high-risk groups, such as adults with high blood pressure who also had left ventricular hypertrophy (LVH). These long-term studies monitored the incidence of major adverse cardiovascular events (MACE). Findings indicate patterns where treatment was associated with differences in the rate of stroke events compared to another treatment in the specific high-risk population studied. The results apply only to the populations studied.

In Diabetic Nephropathy (kidney disease in Type 2 Diabetes), Decara was evaluated in long-term, placebo-controlled clinical trials. Research examined key renal outcomes, including the rate of progression to End-Stage Renal Disease (ESRD) and changes in protein in the urine (proteinuria). Research highlights patterns of reduction in the amount of protein measured. However, evidence is limited regarding whether Decara provides the same renal protection in patients who have kidney disease but do not have concurrent Type 2 diabetes.

Long-term follow-up durations for the major studies typically ranged from three to five years, contributing insight into sustained responses. Data on long-term life expectancy compared to all other treatment classes remain limited. Furthermore, Decara was evaluated in specific special populations, including children and adolescents and older adults, where data show patterns related to blood pressure responses.

Key Studies & References

1. Public Assessment Report (PAR) for Losartan (European Regulatory Documentation)

Common questions about Decara (FAQ)

Q: Does Decara (Losartan) interact with alcohol?

A: Regulatory documents state that alcohol may have an additive effect in lowering blood pressure when taken with Losartan. This combined effect may increase the risk of experiencing symptoms such as dizziness, lightheadedness, or fainting. Official product information suggests caution due to the potential for enhanced blood pressure reduction.

Q: Is there a risk of a serious allergic reaction to Decara?

A: Serious allergic reactions, including angioedema (swelling of the face, lips, throat, and/or tongue), have been reported in patients taking Losartan. The official product information also notes that severe, body-wide allergic reactions (anaphylactic reactions) have been reported.

Q: How should I dispose of unused Decara (Losartan) tablets?

A: Official guidelines indicate that unused Losartan tablets should generally not be flushed down a toilet or drain. The preferred method is using a community drug take-back program. If a program is not available, the guidelines suggest mixing the tablets with an undesirable substance, such as coffee grounds or dirt, placing the mixture in a sealed container, and discarding it in the household trash.

Q: What is the main ingredient in Decara?

A: The active ingredient in the medication Decara is Losartan Potassium. This is the non-peptide, synthetic compound that provides the therapeutic effect of reducing high blood pressure.

Q: Can pregnant women take Decara (Losartan)?

A: Official product information contains a strong warning that Losartan can cause injury and even death to a developing fetus. For this reason, use is strictly contraindicated in the second and third trimesters of pregnancy. If pregnancy is detected, official documents state the medication's use needs to be carefully evaluated, and discontinuation may be necessary.

Q: Can I cut the Decara (Losartan) tablets in half?

A: The safety of cutting a Losartan tablet depends on whether it is scored (has a line in the middle) or not. Information regarding scoring is usually found on the packaging or can be confirmed by a pharmacist. Tablets without a score are generally not intended to be split.

Q: Is Decara available as a generic drug?

A: Yes, according to the official regulatory status, the medication Losartan Potassium, which is the active ingredient in Decara, is widely available as a generic drug.

Q: Who manufactured Decara?

A: The original brand product of Losartan (Cozaar) was initially manufactured by Merck & Co. However, the specific manufacturer of the generic Losartan Potassium product a patient receives may vary. This information is generally listed on the specific prescription bottle or package label.

Q: How long does it take for Decara (Losartan) to start working?

A: Studies and official information indicate that the onset of action for Losartan is typically around 6 hours after the dose is taken. The clinical effects typically persist for approximately 24 hours.

Q: Can I drive or operate machinery while taking Decara?

A: Patients are advised to use caution when driving or operating hazardous machinery, particularly when starting the medication, until they understand how Losartan affects them. Losartan may cause side effects like dizziness, lightheadedness, or fainting.

Decara (Losartan Potassium) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and kept from freezing. Tablets should be kept in a closed container and stored in a dry place to maintain stability.

---

The medication must always be kept out of the sight and reach of children and pets. For disposal, Decara should not be flushed down a toilet or drain. The official method is to use a drug take-back program. If a take-back option is unavailable, unused tablets must be mixed with an undesirable substance (e.g., dirt, coffee grounds), placed into a sealed container, and then discarded in the household trash.